Market Place
Sourcing Support
Rosen Law Firm Urges aTyr Pharma Stockholders With Losses
10 Oct 2025 //
PHARMIWEB
aTyr Pharma Announces Inducement Grants Under Nasdaq Rule
16 May 2025 //
GLOBENEWSWIRE
aTyr Pharma to Participate in April Investor Conferences
03 Apr 2025 //
GLOBENEWSWIRE
aTyr Pharma Appoints Dalia R. Rayes as Head of Global Efzofitimod
26 Mar 2025 //
GLOBENEWSWIRE
aTyr Pharma Announces Q4 and Full Year 2024 Results and Update
13 Mar 2025 //
GLOBENEWSWIRE
aTyr Pharma: Efzofitimod`s Immunomodulatory Activity in Science
12 Mar 2025 //
GLOBENEWSWIRE
aTyr Pharma to Present at Upcoming Investor Conferences
31 Oct 2024 //
GLOBENEWSWIRE
aTyr Pharma Appoints Jayant Aphale As VP Of Technical Operations
06 Aug 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Research Study with Stanford Medicine
30 Jul 2024 //
GLOBENEWSWIRE
ATYR Pharma Completes Enrollment For Phase 3 Efzofitimod Trial
22 Jul 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03 Jun 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 May 2024 //
GLOBENEWSWIRE
aTyr Pharma to Present at Upcoming Investor Conferences
06 May 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
02 May 2024 //
GLOBENEWSWIRE
aTyr Pharma to Participate in April Investor Conferences
01 Apr 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results
14 Mar 2024 //
GLOBENEWSWIRE
aTyr to Webcast Conference Reporting Q4 and Full Year End 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces EAP for EFZO-FIT¢ Clinical Trial Participants
21 Feb 2024 //
GLOBENEWSWIRE
aTyr to Present Posters Highlighting Importance of Neuropilin-2
29 Jan 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Emeritus Dr. Wayne A. I. Frederick as Advisor
18 Jan 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
09 Nov 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
aTyr to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 Aug 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
09 Aug 2023 //
GLOBENEWSWIRE
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research
06 Jun 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
25 May 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at 2023 RBC Capital Markets Global Healthcare Conference
11 May 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
aTyr and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting
20 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results
09 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at March Investor Conferences
08 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma to Webcast Conference Call Reporting Q4 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Pricing of Public Offering of Common Stock
09 Feb 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Commencement of Public Offering of Common Stock
08 Feb 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
15 Dec 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10 Nov 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Publication of +VE Data Ph 1b/2a of Efzofitimod
09 Nov 2022 //
GLOBENEWSWIRE
aTyr to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present at the Jefferies London Healthcare Conference
25 Oct 2022 //
GLOBENEWSWIRE
aTyr Announces Research Collaboration with Dualsystems Biotech AG
12 Oct 2022 //
GLOBENEWSWIRE
aTyr Pharma to Participate in RBC Biotech Expert Insights Pulmonary/Lung Disease
04 Oct 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin
29 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™
27 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for SSc-ILD
14 Sep 2022 //
PRESS RELEASE
aTyr Pharma to Present at the H.C. Wainwright 24th AnnualGIC 2022
06 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present Poster at the European Respiratory Society (ERS)
01 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
15 Aug 2022 //
GLOBENEWSWIRE
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923)
11 Aug 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present Findings from its tRNA Synthetase Platform
13 Jun 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces PIII Study of Efzofitimod in Pulmonary Sarcoidosis
16 May 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 May 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present at Upcoming Investor Conferences in May
10 May 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
09 May 2022 //
GLOBENEWSWIRE
aTyr Pharma to Webcast First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces FDA ODD for Efzofitimod (ATYR1923) in Systemic Sclerosis
13 Apr 2022 //
GLOBENEWSWIRE
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810
11 Apr 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the ATS
01 Apr 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 Mar 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Q4 and Full Year 2021 Results; Provides Corporate Update
14 Mar 2022 //
GLOBENEWSWIRE
